The European Medicines Agency’s (EMA) Emergency Task Force (ETF) announced on Wednesday 27 July that it had undertaken an analysis of data on sabizabulin, an oral treatment originally developed as an anti-cancer therapy by Veru Inc. to assess the use of this medicine in the treatment of Covid-19.
Veru has not yet formally applied for market authorisation and this is not an ongoing evaluation.
This is the first review conducted by the ETF under Article 18 (3 and 4) of Regulation...